[P02BB01, trichlorfon, The risk or severity of adverse effects can be increased when Metrifonate is combined with Carbamoylcholine.]
[J01GA01, streptomycin, The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Streptomycin.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Carbamoylcholine.]
[N06DA01, tacrine, The risk or severity of adverse effects can be increased when Tacrine is combined with Carbamoylcholine.]
[R03CC03, terbutaline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Carbamoylcholine.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Thiotepa is combined with Carbamoylcholine.]
[B02AB01, aprotinin, The risk or severity of adverse effects can be increased when Aprotinin is combined with Carbamoylcholine.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Timolol is combined with Carbamoylcholine.]
[S01AA12, tobramycin, The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Tobramycin.]
[S01EB04, demecarium, The risk or severity of adverse effects can be increased when Demecarium is combined with Carbamoylcholine.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Carbamoylcholine.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Carbamoylcholine.]
[S01AA05, tyrothricin, The risk or severity of adverse effects can be increased when Tyrothricin is combined with Carbamoylcholine.]
[C07AB03, atenolol, The risk or severity of adverse effects can be increased when Atenolol is combined with Carbamoylcholine.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Carbamoylcholine.]
[C07AB04, acebutolol, The risk or severity of adverse effects can be increased when Acebutolol is combined with Carbamoylcholine.]
[A16AA06, betaine, The risk or severity of adverse effects can be increased when Betaine is combined with Carbamoylcholine.]
[S01ED02, betaxolol, The risk or severity of adverse effects can be increased when Betaxolol is combined with Carbamoylcholine.]
[S01AA15, dihydrostreptomycin, The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Dihydrostreptomycin.]
[S03AA06, gentamicin, The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Gentamicin.]
[C07AA19, bupranolol, The risk or severity of adverse effects can be increased when Bupranolol is combined with Carbamoylcholine.]
[N06DA03, rivastigmine, The risk or severity of adverse effects can be increased when Rivastigmine is combined with Carbamoylcholine.]
[R03CC12, bambuterol, The risk or severity of adverse effects can be increased when Bambuterol is combined with Carbamoylcholine.]
[C07AB07, bisoprolol, The risk or severity of adverse effects can be increased when Bisoprolol is combined with Carbamoylcholine.]
[C07AA17, bopindolol, The risk or severity of adverse effects can be increased when Bopindolol is combined with Carbamoylcholine.]
[N01BX04, capsaicin, The risk or severity of adverse effects can be increased when Capsaicin is combined with Carbamoylcholine.]
[C07AG02, carvedilol, The risk or severity of adverse effects can be increased when Carvedilol is combined with Carbamoylcholine.]
[J01GB14, plazomicin, The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Plazomicin.]
[C07AB08, celiprolol, The risk or severity of adverse effects can be increased when Celiprolol is combined with Carbamoylcholine.]
[N05AA01, chlorpromazine, The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Carbamoylcholine.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Carbamoylcholine.]
[J01GB12, arbekacin, The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Arbekacin.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Carbamoylcholine.]
[J01XB01, colistin, The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Colistin.]
[H01AX01, pegvisomant, The risk or severity of adverse effects can be increased when Pegvisomant is combined with Carbamoylcholine.]
[C07AA14, mepindolol, The risk or severity of adverse effects can be increased when Mepindolol is combined with Carbamoylcholine.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Carbamoylcholine.]
[C07AB12, nebivolol, The risk or severity of adverse effects can be increased when Nebivolol is combined with Carbamoylcholine.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Carbamoylcholine.]
[P02CB02, diethylcarbamazine, The risk or severity of adverse effects can be increased when Diethylcarbamazine is combined with Carbamoylcholine.]
[N07AA03, distigmine, The risk or severity of adverse effects can be increased when Distigmine is combined with Carbamoylcholine.]
[V04CX07, edrophonium, The risk or severity of adverse effects can be increased when Edrophonium is combined with Carbamoylcholine.]
[C07AB13, talinolol, The risk or severity of adverse effects can be increased when Talinolol is combined with Carbamoylcholine.]
[C07AA16, tertatolol, The risk or severity of adverse effects can be increased when Tertatolol is combined with Carbamoylcholine.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Profenamine is combined with Carbamoylcholine.]
[A02BA04, nizatidine, The risk or severity of adverse effects can be increased when Nizatidine is combined with Carbamoylcholine.]
[S01AA07, framycetin, The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Framycetin.]
[N06DA04, galantamine, The risk or severity of adverse effects can be increased when Galantamine is combined with Carbamoylcholine.]
[C07AB09, esmolol, The risk or severity of adverse effects can be increased when Esmolol is combined with Carbamoylcholine.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Carbamoylcholine.]
[S01EB07, isoflurophate, The risk or severity of adverse effects can be increased when Isoflurophate is combined with Carbamoylcholine.]
[R03CB01, isoproterenol, The risk or severity of adverse effects can be increased when Isoprenaline is combined with Carbamoylcholine.]
[S01AA24, kanamycin, The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Kanamycin.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Carbamoylcholine.]
[C07AG01, labetalol, The risk or severity of adverse effects can be increased when Labetalol is combined with Carbamoylcholine.]
[N07AA30, ambenonium, The risk or severity of adverse effects can be increased when Ambenonium is combined with Carbamoylcholine.]
[S01AA21, amikacin, The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Amikacin.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Carbamoylcholine.]
[P01BC02, mefloquine, The risk or severity of adverse effects can be increased when Mefloquine is combined with Carbamoylcholine.]
[N06DX01, memantine, The risk or severity of adverse effects can be increased when Memantine is combined with Carbamoylcholine.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Carbamoylcholine.]
[C07AB02, metoprolol, The risk or severity of adverse effects can be increased when Metoprolol is combined with Carbamoylcholine.]
[C07AA12, nadolol, The risk or severity of adverse effects can be increased when Nadolol is combined with Carbamoylcholine.]
[S03AA01, neomycin, The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Neomycin.]
[S01EB06, neostigmine, The risk or severity of adverse effects can be increased when Neostigmine is combined with Carbamoylcholine.]
[S01AA23, netilmicin, The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Netilmicin.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Carbamoylcholine.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Carbamoylcholine.]
[J04AB30, capreomycin, The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Capreomycin.]
[A07AA06, paromomycin, The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Paromomycin.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Penbutolol is combined with Carbamoylcholine.]
[V03AB19, physostigmine, The risk or severity of adverse effects can be increased when Physostigmine is combined with Carbamoylcholine.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Carbamoylcholine.]
[C07AB01, practolol, The risk or severity of adverse effects can be increased when Practolol is combined with Carbamoylcholine.]
[C01BA02, procainamide, The risk or severity of adverse effects can be increased when Procainamide is combined with Carbamoylcholine.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Carbamoylcholine.]
[C01BC03, propafenone, The risk or severity of adverse effects can be increased when Propafenone is combined with Carbamoylcholine.]
[C07AA05, propranolol, The risk or severity of adverse effects can be increased when Propranolol is combined with Carbamoylcholine.]
[N07AA02, pyridostigmine, The risk or severity of adverse effects can be increased when Pyridostigmine is combined with Carbamoylcholine.]
[J01GB08, sisomicin, The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Sisomicin.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Sotalol is combined with Carbamoylcholine.]
